Join the Crohn's Disease - Maintenance group to help and get support from people like you.
Crohn's Disease - Maintenance News
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
WEDNESDAY, July 17, 2024 – For patients with moderate-to-severe Crohn disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 – There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD)...
Top-Down Treatment Superior for Crohn Disease
TUESDAY, March 5, 2024 – Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up treatment, according to a...
Treating Crohn's Sooner, More Aggressively Greatly Improves Outcomes: Study
MONDAY, Feb. 26, 2024 – In a finding that suggests sooner is better than later, a new trial shows that giving advanced treatment early to Crohn’s patients can dramatically improve their gut health. A...
Higher Use of Any Rx Medications Seen Years Before IBD Diagnosis
FRIDAY, Jan. 19, 2024 – Individuals with inflammatory bowel disease (IBD) universally show increased prescription medication use years before diagnosis, according to a study published in the...
Malnutrition Often Seen in Patients Treated for IBD
FRIDAY, Jan. 12, 2024 – Some patients seen in an inflammatory bowel disease (IBD) clinic screen positive for malnutrition, according to a research letter published online Nov. 20 in Gastro Hep ...
Persistent Fluorinated Chemicals Tied to Higher Risk for Inflammatory Bowel Disease
FRIDAY, Jan. 12, 2024 – Perfluoroalkyl and polyfluoroalkyl substance (PFAS) exposure is associated with later occurrence of inflammatory bowel disease (IBD), according to a research letter published...
Inflammatory Bowel Disease Phenotypes Vary by Race, Birthplace
MONDAY, Jan. 8, 2024 – For patients with inflammatory bowel disease (IBD), phenotype varies by race, and foreign-born patients of all races have later onset and milder disease, according to a study...
Changes in Biochemical, Hematological Parameters Seen Before IBD Diagnosis
MONDAY, Dec. 11, 2023 – Changes in multiple biochemical and hematological parameters occur up to eight years before diagnosis of Crohn disease and up to three years before diagnosis of ulcerative...
Histologic Inflammation With IBD Tied to Serious Infections
FRIDAY, Dec. 8, 2023 – Histologic inflammation with inflammatory bowel disease (IBD) is an independent risk factor for serious infections, according to a study published online Oct. 29 in Clinical ...
Higher Visceral Adipose Tissue May Need Higher Infliximab Levels for IBD Remission
WEDNESDAY, Nov. 15, 2023 – Patients with inflammatory bowel disease (IBD) and high visceral adipose tissue (VAT) may have more difficulty achieving higher infliximab levels necessary to achieve...
Inflammatory Bowel Disease Increases Risk for Later Arrhythmias
MONDAY, Nov. 6, 2023 – Patients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later...
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 – Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open. Osama Hamid, M.B.B.S., from the Cleveland...
First Biosimilar, Tyruko, Approved to Treat Multiple Sclerosis
FRIDAY, Aug. 25, 2023 – The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of...
AI-Based Radiomic Model Improves Diagnosis of Crohn Disease
THURSDAY, Aug. 10, 2023 – In a study published Aug. 2 in the American Journal of Roentgenology, a radiomic machine learning model predicted Crohn's disease diagnosis with better performance than two...
Ask a question
To post your own question to this support group, sign in or create an account.